Search company, investor...

BioMarck Pharmaceuticals


Unattributed | Alive

Total Raised


Last Raised

$750K | 6 yrs ago

About BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Headquarters Location

2530 Meridian Parkway Suite 300

Durham, North Carolina, 27713,

United States


Missing: BioMarck Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioMarck Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioMarck Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioMarck Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

BioMarck Pharmaceuticals Patents

BioMarck Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Immunology
  • Protein domains
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Transcription factors, DNA, RNA, Nucleic acids


Application Date


Grant Date



Related Topics

Molecular biology, Transcription factors, DNA, RNA, Nucleic acids



Latest BioMarck Pharmaceuticals News

Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit

Jul 7, 2021

July 07, 2021 07:07 AM Eastern Daylight Time NEWTOWN, Pa.--( BUSINESS WIRE )-- Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on developing peptides that inhibit MARCKS to treat patients with inflammatory diseases, today announced that data from clinical and preclinical studies of BIO-11006, the Company’s lead peptide, will be presented during the 2021 ARDS Drug Development Summit, a virtual event being held July 13 – 15, 2021. In the Phase 2 clinical study, rapid and faster improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo (half normal saline), together with decreases in pro-inflammatory cytokines. At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm. BIO-11006 was effective in three preclinical mouse models, lipopolysaccharide (LPS), Strep. pneumoniae and lipoteichoic acid (LTA). Treatment with BIO-11006 prevented development of ARDS, reversed established ARDS and prevented neutrophil influx into the lungs. Professor Kenneth Adler, PhD, Professor of Cell Biology at North Carolina State University’s College of Veterinary Medicine, and Presenter at the Summit, commented, “Compelling evidence of efficacy has been demonstrated with BIO-11006 in preclinical models and in a Phase 2 study. It is hoped that these results can now be repeated in a larger clinical trial currently being planned.” The presentation will be available after the summit on the Biomarck website in the Publications section . About Biomarck Biomarck Pharmaceuticals, Ltd., is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, confirming safety and efficacy in these three potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis. Contacts

BioMarck Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioMarck Pharmaceuticals Rank

BioMarck Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is BioMarck Pharmaceuticals's headquarters?

    BioMarck Pharmaceuticals's headquarters is located at 2530 Meridian Parkway, Durham.

  • What is BioMarck Pharmaceuticals's latest funding round?

    BioMarck Pharmaceuticals's latest funding round is Unattributed.

  • How much did BioMarck Pharmaceuticals raise?

    BioMarck Pharmaceuticals raised a total of $21.5M.

  • Who are the investors of BioMarck Pharmaceuticals?

    Investors of BioMarck Pharmaceuticals include National Institutes of Health.

  • Who are BioMarck Pharmaceuticals's competitors?

    Competitors of BioMarck Pharmaceuticals include Aerie, Oligomerix, Sound Pharmaceuticals, Acumen Pharmaceuticals, Portola Pharmaceuticals, VIVUS, Mutabilis, Keryx Biopharmaceuticals, Orexigen Therapeutics, BaroFold and 48 more.

Compare BioMarck Pharmaceuticals to Competitors

Longevica Logo

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.